Our results expand the understanding of the role of brain border‐associated myeloid cells in exacerbating ischemic stroke and propose novel treatment that targets CXCL2+ neutrophils for no‐flow‐related neurological deficits following cerebral ischemic stroke. Here, CXCL2 is linked to ischemic stroke.